Your browser doesn't support javascript.
loading
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin, Alexander M; Tomasson, Michael H; Arnulf, Bertrand; Bahlis, Nizar J; Miles Prince, H; Niesvizky, Ruben; Rodrίguez-Otero, Paula; Martinez-Lopez, Joaquin; Koehne, Guenther; Touzeau, Cyrille; Jethava, Yogesh; Quach, Hang; Depaus, Julien; Yokoyama, Hisayuki; Gabayan, Afshin Eli; Stevens, Don A; Nooka, Ajay K; Manier, Salomon; Raje, Noopur; Iida, Shinsuke; Raab, Marc-Steffen; Searle, Emma; Leip, Eric; Sullivan, Sharon T; Conte, Umberto; Elmeliegy, Mohamed; Czibere, Akos; Viqueira, Andrea; Mohty, Mohamad.
Afiliación
  • Lesokhin AM; Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA. lesokhia@mskcc.org.
  • Tomasson MH; Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
  • Arnulf B; Hôpital Saint-Louis, Paris, France.
  • Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
  • Miles Prince H; Epworth Healthcare and University of Melbourne, Melbourne, Victoria, Australia.
  • Niesvizky R; Weill Cornell Medical College/New York Presbyterian Hospital, New York City, NY, USA.
  • Rodrίguez-Otero P; Clinica Universidad de Navarra, Madrid, Spain.
  • Martinez-Lopez J; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Koehne G; Miami Cancer Institute, Miami, FL, USA.
  • Touzeau C; University Hospital of Nantes, Nantes, France.
  • Jethava Y; Indiana Blood & Marrow Transplant, Indianapolis, IN, USA.
  • Quach H; University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Depaus J; Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
  • Yokoyama H; Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Gabayan AE; Beverly Hills Cancer Center, Beverly Hills, CA, USA.
  • Stevens DA; Norton Cancer Center, Louisville, KY, USA.
  • Nooka AK; Winship Cancer Institute, Atlanta, GA, USA.
  • Manier S; Lille University Hospital and INSERM UMR-S1277, Lille, France.
  • Raje N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Iida S; Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Raab MS; Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Searle E; The Christie Hospital, The University of Manchester, Manchester, UK.
  • Leip E; Pfizer Inc, Cambridge, MA, USA.
  • Sullivan ST; Pfizer Inc, Cambridge, MA, USA.
  • Conte U; Pfizer Inc, New York, NY, USA.
  • Elmeliegy M; Pfizer Inc, San Diego, CA, USA.
  • Czibere A; Pfizer Inc, New York, NY, USA.
  • Viqueira A; Pfizer SLU, Madrid, Spain.
  • Mohty M; Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France.
Nat Med ; 29(9): 2259-2267, 2023 09.
Article en En | MEDLINE | ID: mdl-37582952
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos